Sensei biotherapeutics signs cooperative research and development agreement (crada) with the national cancer institute (nci) to expand development plan for sns-101, a conditionally active vista-blocking antibody

Boston, feb. 06, 2023 (globe newswire) -- sensei biotherapeutics, inc. (nasdaq: snse), an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that it has signed a cooperative research and development agreement (crada) with the national cancer institute (nci), part of the national institutes of health (nih), to expand the development of sns-101, a conditionally active, ph-selective vista-blocking antibody.
SNSE Ratings Summary
SNSE Quant Ranking